Ritesh R. Kotecha

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates

Chung‐Han Lee, Martin H. Voss, Maria I. Carlo et al. · Journal of Clinical Oncology · 2022 · 182 citations · Full text

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma

Mattias Carlsten, Neha Korde, Ritesh R. Kotecha et al. · Clinical Cancer Research · 2016 · 162 citations · Full text

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors

Amishi Y. Shah, Ritesh R. Kotecha, Emily Lemke et al. · European Journal of Cancer · 2019 · 120 citations · Full text

Urology, Genitourinary Cancer, Medicine +4

Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma

Jack P. Gleeson, Ines Nikolovski, Renzo G. DiNatale et al. · Clinical Cancer Research · 2021 · 84 citations · Full text

PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine

Ramin S. Herati, David A. Knorr, Laura A. Vella et al. · Nature Immunology · 2022 · 73 citations · Full text

Vaccination, Seasonal Influenza Vaccine, Humoral Immune Responses +12